Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 251-261 , July 2008

Positron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction

  • Daniel H.S. Silverman, MD, PhD

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA.
    • Corresponding Author InformationAddress reprint requests to Daniel H.S. Silverman, MD, PhD, Nuclear Medicine Clinic, CHS AR-144, UCLA School of Medicine, MC694215, Los Angeles, CA 90095-6942.
    • ,
  • Lisa Mosconi, PhD

      Affiliations

    • New York University School of Medicine, New York, NY.
    • ,
  • Linda Ercoli, PhD

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA.
    • ,
  • Wei Chen, MD, PhD

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA.
    • Kaiser Permanente of Southern California, Woodland Hills, CA.
    • ,
  • Gary W. Small, MD

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA.

References 

  1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366:2112–2117
  2. Alzheimer's Association: Alzheimer's Disease Facts and Figures. http://www.alz.org/alzheimers_disease_facts_figures.aspAccessed March 12, 2008
  3. Powell MR, Smith GE, Knopman DS, et al. Cognitive measures predict pathologic Alzheimer disease. Arch Neurol. 2006;63:865–868
  4. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med. 1995;122:422–429
  5. Hoffman RS. Diagnostic errors in the evaluation of behavioral disorders. JAMA. 1982;248:964–967
  6. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of AD in a community-based case series. J Am Geriatr Soc. 1999;47:564–569
  7. McDaniel LD, Lukovits T, McDaniel KD. AD: The problem of incorrect clinical diagnosis. J Geriatr Psychiatry Neurol. 1993;6:230–234
  8. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review) (Report of the Quality Standards Subcommittee of the American Academy of Neurology). Neurology. 2001;56:1143–1153
  9. Birks J, Iakovidou V, Tsolaki M. Rivastigmine for AD (Cochrane Database Systemic Review). In: The Cochrane Library. 4:2000;:CD001191. (Available from: Update Software Ltd., Oxford, U.K. Accessed August 30, 2000)
  10. Burns A, Rossor M, Hecker J, et al. International Donepezil Study Group The effects of donepezil in AD: Results from a multinational trial. Dementia. 1999;10:237–244
  11. Corey-Bloom J, Anand R, Veach J ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe AD. Int J Geriatr Psychopharmacol. 1998;1:55–65
  12. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with AD (The Tacrine Study Group). JAMA. 1994;271:985–991
  13. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension (The Galantamine USA-1 Study Group). Neurology. 2000;54:2261–2268
  14. Rogers SL, Friedhoff LT, Apter JT, et al. The efficacy and safety of donepezil in patients with AD: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293–303
  15. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of Rivastigmine in patients with AD: International randomized controlled trial. BMJ. 1999;318:633–638
  16. Knopman D, Schneider LS, Davis K, et al. Long-term tacrine (Cognex) treatment effects on nursing home placement and mortality (The Tacrine Study Group). Neurology. 1996;47:166–177
  17. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of AD. Clin Ther. 1998;20:838–850
  18. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for AD. N Engl J Med. 1997;336:1216–1222
  19. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of AD. Biol Psychiatry. 2001;49:289–299
  20. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with AD. Neurology. 1998;50:1222–1230
  21. Tariot P, Solomon P, Morris J, et al. Galantamine Study Group A 5-month, randomized, placebo-conrtrolled trial of galantamine in AD. Neurology. 2000;54:2269–2276
  22. Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioral symptoms in AD patients. J Clin Psychiatry. 2000;61:487–492
  23. Fago JP. Dementia: Causes, evaluation, and management. Hosp Pract (Off Ed). 2001;36:59–69
  24. Imbimbo BP, Verdelli G, Martelli P, et al. Two-year treatment of AD with eptastigmine. Dement Geriatr Cogn Disord. 1999;10:139–147
  25. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of AD: An interim analysis of the results of a US multicentre open label extension Study. Eur Neuropsychopharmacol. 1998;8:67–75
  26. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease (Donepezil Study Group). Arch Neurol. 2001;58:427–433
  27. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? (A review of clinical and population-based studies). Int J Geriatr Psychiatry. 2000;15:983–991
  28. Jorm AF, Butterworth P, Anstey KJ, et al. Memory complaints in a community sample aged 60-64 years: associations with cognitive functioning, psychiatric symptoms, medical conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. Psychol Med. 2004;34:1495–1506
  29. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure and normal values in the conscious and anesthesized albino rat. J Neurochem. 1977;28:897–916
  30. Huang SC, Phelps ME, Hoffman EJ, et al. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol. 1980;238:E69–E82
  31. Kuhl DE, Phelps ME, Kowell AP, et al. Effects of stroke on local cerebral metabolism and perfusion: mapping local metabolism and perfusion in normal and ischemic brain by emission computed tomography of 18FDG and 13NH3. Ann Neurol. 1980;8:47–60
  32. Mazziotta JC, Phelps ME, Miller J, et al. Tomographic mapping of human cerebral metabolism: normal unstimulated state. Neurology. 1981;31:503–516
  33. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxyglucose: Validation of method. Ann Neurol. 1979;6:371–388
  34. Reivich N, Kuhl D, Wolf A, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127–137
  35. Moeller JR, Ishikawa T, Dhawan V, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab. 1996;16:385–398
  36. Yamaji S, Ishii K, Sasaki M, et al. Evaluation of standardized uptake value to assess cerebral glucose metabolism. Clin Nucl Med. 2000;25:11–16
  37. Schultz SK, O'Leary DS, Boles Ponto LL, et al. Age-related changes in regional cerebral blood flow among young to mid-life adults. Neuroreport;. 1999;10:2493–2496
  38. Meltzer CC, Cantwell MN, Greer PJ, et al. Does cerebral blood flow decline in healthy aging? (A PET study with partial-volume correction). J Nucl Med. 2000;41:1842–1848
  39. Mazziotta JC, Phelps ME. Positron emission tomography studies of the brain. In:  Phelps M,  Mazziotta J,  Schelbert H editor. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York, NY: Raven Press; 1986;p. 493–579
  40. Apostolova LG, Dinov ID, Zoumalan C, et al. MR-Guided 3D PET Mapping of Longitudinal Changes in Regional Cerebral Metabolism of Normal Subjects. 2006;International Conference on Alzheimer's Disease (ICAD2006), Madrid, (abstr)
  41. Silverman DHS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–2127
  42. Herholz K, Nordberg A, Salmon E, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord. 1999;10:494–504
  43. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85–94
  44. Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45:594–607
  45. Silverman DHS, Truong CT, Kim SK, et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab. 2003;80:350–355
  46. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:6037–6042
  47. Bench CJ, Friston KJ, Brown RG, et al. Regional cerebral blood flow in depression measured by positron emission tomography: The relationship with clinical dimensions. Psychol Med. 1993;23:579–590
  48. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–1992
  49. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001;98:10966–10971
  50. Jack CR, Peterson RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484–489
  51. Rusinek H, De Santi S, Frid D, et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology. 2003;229:691–696
  52. Jack CR, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591–600
  53. den Heijer T, Geerlings MI, Hoebeek FE, et al. Use of hippocampal and amygdala volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry. 2006;63:57–62
  54. Chetelat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain. 2008;131:60–71
  55. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer's disease: Automated FDG-PET image analysis. Neurology. 2005;64:1860–1867
  56. Ibanez V, Pietrini P, Alexander GE, et al. Regional gluose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 1999;50:1585–1593
  57. Nestor PJ, Fryer TD, Smielewski P, et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol. 2003;54:343–351
  58. Mosconi L, De Santi S, Li Y, et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med. 2006;33:210–221
  59. Chetelat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003;60:1374–1377
  60. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–1113
  61. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12:851–855
  62. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;2005 46:1625–1632
  63. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62:1728–1733
  64. Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E epsilon-4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 1997;277:822–824
  65. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942–947
  66. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N Eng J Med. 1996;334:752–758
  67. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101:284–289
  68. Silverman DHS, Hussain SA, Ercoli LM, et al. Detection of differences in regional cerebral metabolism associated with genotypic and educational risk factors for dementia. In: 2000;p. 422–427Proceedings of the International Conference on Mathematics and Engineering Techniques in Medicine and Biological Sciences
  69. Benson DF, Kuhl DE, Phelps ME, et al. Positron emission computed tomography in the diagnosis of dementia. Trans Am Neurol Assoc. 1981;106:68–71
  70. Farkas T, Ferris SH, Wolf AP, et al. 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. Am J Psychiatry. 1982;139:352–353
  71. Foster NL, Chase TN, Fedio P, et al. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology. 1983;33:961–965
  72. Frackowiak RS, Pozzilli C, Legg NJ, et al. Regional cerebral oxygen supply and utilization in dementia (A clinical and physiological study with oxygen-15 and positron tomography). Brain. 1981;104:753–778
  73. Devous MD. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med Mol Imaging. 2002;29:1685–1696
  74. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol &. 2008;161–172
  75. Silverman DHS, Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin N Am. 2005;43:67–77
  76. Silverman DHS, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of AD. Clin Positron Imaging. 1999;2:119–130
  77. Mielke R, Schroder R, Fink GR, et al. Regional cerebral glucose metabolism and postmortem pathology in AD. Acta Neuropathol (Berl). 1996;91:174–179
  78. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med. 1994;35:391–398
  79. Tedeschi E, Hasselbalch SG, Waldemar G, et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry. 1995;59:608–615
  80. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41:1920–1928
  81. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(5 suppl):1S–93S
  82. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review) (Report of the Quality Standards Subcommittee of the American Academy of Neurology). Neurology. 2001;56:1143–1153
  83. Ackerman RH, Correia JA, Alpert NM, et al. Positron imaging in ischemic stroke disease using compounds labeled with oxygen-15 (Initial results of clinicophysiologic correlations). Arch Neurol. 1981;38:537–543
  84. Baron JC, Bousser MG, Rey A, et al. Reversal of focal “misery-perfusion syndrome” by extra-intracranial arterial bypass in hemodynamic cerebral ischemia: A case study with 15O positron tomography. Stroke. 1981;12:454–459
  85. Grubb RL, Derdeyn CP, Fritsch SM, et al. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA. 1998;280:1055–1060
  86. Yamauchi H, Fukuyama H, Nagahama Y, et al. Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases. J Nucl Med. 1999;40:1992–1998
  87. Heiss WD, Grond M, Thiel A, et al. Tissue at risk of infarction rescued by early reperfusion: A positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cereb Blood Flow Metab. 1998;18:1298–1307
  88. Marchal G, Benali K, Iglesias S, et al. Voxel-based mapping of irreversible ischaemic damage with PET in acute stroke. Brain. 1999;122:2387–2400
  89. Nemoto EM, Yonas H, Pindzola RR, et al. PET OEF reactivity for hemodynamic compromise in occlusive vascular disease. J Neuroimaging. 2007;17:54–60
  90. Endo H, Inoue T, Ogasawara K, et al. Quantitative assessment of cerebral hemodynamics using perfusion-weighted MRI in patients with major cerebral artery occlusive disease: Comparison with positron emission tomography. Stroke. 2006;37:388–389
  91. Takasawa M, Jones PS, Guadagno JV, et al. How reliable is perfusion MR in acute stroke? (Validation and determination of the penumbra threshold against quantitative PET). Stroke. 2008;E-pub Feb 7, PMID: 18258831
  92. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol. 1999;45:358–368
  93. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2002;10:24–35
  94. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319
  95. Small GW, Kepe V, Ercoli L, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–2663
  96. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603–1606
  97. Pappata S, Salvatore E, Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J Neuroimaging. 2008;18:111–124
  98. Kepe V, Barrio JR, Huang SC, et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2006;103:702–707
  99. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol;. 1999;56:303–308
  100. Alexander GE, Chen K, Pietrini P, et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159:738–745
  101. Reiman EM, Caselli RJ, Chen K, et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:3334–3339
  102. Small GW, Silverman DHS, Siddarth P, et al. Effects of a 14-day healthy aging lifestyle program on cognition and brain function. Am J Geriatr Psychiatry. 2006;14:538–545

PII: S0001-2998(08)00029-9

doi: 10.1053/j.semnuclmed.2008.02.006

Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 251-261 , July 2008

Article Tools

* Image Usage & Resolution